Journal of Thyroid Disorders & Therapy
Open Access
ISSN: 2167-7948
+44 1300 500008
ISSN: 2167-7948
+44 1300 500008
Laura Raimondi and Annunzitina Laurino
University of Florence, Italy
Posters & Accepted Abstracts: Thyroid Disorders Ther
3-iodothyronamine (T1AM) is a trace amine derived from Thyroid hormone metabolism circulating in rodents and humans whose physiological role remains to be discovered. Much is instead known on T1AM pharmacological effects even if the the mechanism(s) responsible for such effects are only partially exploited. T1AM pharmacodynamics features include interaction at trace amine receptors (subtypes 1-3-8), alfa2 and b2 adrenergic receptors. Interestingly, at alfa-2 and TAAR8 the amine behaves as an inverse agonist. More recently, T1AM was reported as a modulator of TRPM8, thus suggesting T1AM as a multi-target molecule and as a possible modulator of G-protein coupled receptors. Accordingly, we have recently described T1AM as an antagonist at muscarinic type 3 receptor. In the last years we have been involved in exploiting pharmacological effects of T1AM low doses in mice. In recent years we have our results suggest T1AM has the potential to behave as a neuromediator of the histaminergic signaling. In particular we found that the amine is able to modify mice behavior including feeding, learning and memory, pain threshold. All these effects were due, at least in part, to the production of its oxidative metabolite, the TA1. Interstingly enough, the TA1/T1AM endogenous levels averaging 1.7% is maintained also after pharmacological administration of T1AM. All the effects of T1AM and of TA1so far studied are mediated by the release of histamine. Our data indicate the existence of a novel network connecting the Thyroid with histamine. Furthermore, accumulation of T1AM and/or TA1 may account for the histaminergic and antimuscarinic effects observed in Thyroid patients including itch, hyperalgesia and disturbances of sleep/arousal cycle.
Email: laura.raimondi@unifi.it